Breaking News
March 25, 2018 - Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
March 25, 2018 - ENDO 2018 Roundup: New Tx Options for Obesity, Low BMD, Benign Thyroid Disease
March 25, 2018 - The protein that prevents loose teeth
March 24, 2018 - Morning Break: Skip the Finger Exam? Self C-Section; Toxic Toenail Fungus
March 24, 2018 - 3-D simulations reveal synergistic mechanisms of the human heart
March 24, 2018 - Newly designed three-part molecule shows promise to treat breast cancers
March 24, 2018 - Pubertal hormones not responsible for changes in social behavior during adolescence
March 24, 2018 - Waning Vaccine Protection May Be Driving Rise in U.S. Mumps Cases
March 24, 2018 - Folic Acid in Utero Tied to Food Allergy Risk
March 24, 2018 - Trial shows safety of drugs for irregular heartbeat patients undergoing treatment
March 24, 2018 - Penn State psychologists shed light on false memories in older adults
March 24, 2018 - Patients who self-discharge should be viewed more positively, say researchers
March 24, 2018 - Wearable brain scanner enables brain imaging whilst moving
March 24, 2018 - Trump Signs $1.3 Trillion Spending Bill, Averts Shutdown
March 24, 2018 - Two drugs prevent heart problems in breast cancer patients
March 24, 2018 - Research provides better understanding of how some cancer cells resist treatment
March 24, 2018 - Certain nutrients found in food may help reduce symptoms of psychotic illness
March 24, 2018 - AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
March 24, 2018 - AHRQ Is in Trouble | Medpage Today
March 24, 2018 - Could a pap test spot more than just cervical cancer?
March 24, 2018 - Men have greater hospital readmission risk following firearm injury, study shows
March 24, 2018 - Pediatric psychologist shares 11 warning signs of childhood depression
March 24, 2018 - OncoBreak: ‘I Was Normal Once’; Ending Cervical Cancer; Mammo Controversy
March 24, 2018 - Gum Disease by the Numbers
March 24, 2018 - Studies show tool can identify individual needs, supports to help youths with autism, intellectual disabilities
March 24, 2018 - Study reveals cause of extreme nausea in pregnancy
March 24, 2018 - New findings highlight need to reconsider cervical cancer screening guidelines
March 24, 2018 - Smartwatch App Might Help Detect A-Fib
March 24, 2018 - TAVR Reasonable for Low-Flow, Low-Gradient Aortic Stenosis
March 24, 2018 - Kids with severe brain injuries may develop ADHD: study
March 24, 2018 - Researchers explore ways to help older adults taper off and stop using sedatives
March 24, 2018 - Back pain being mismanaged globally
March 24, 2018 - Fingerprint test accurately and noninvasively detects heroin, cocaine users
March 24, 2018 - Leading experts to promote cardiovascular health at EuroPrevent 2018
March 24, 2018 - A Role for Rituximab in Lupus?
March 24, 2018 - New osteoarthritis genes discovered
March 24, 2018 - Maternal intake of DHA supplement linked to higher fat-free body mass in children
March 24, 2018 - Royal College of Pathologists‘ bulletin provides summary of Tissue Handling Workshop
March 24, 2018 - Maternal alcohol use early in pregnancy may be risk factor for infant abdominal malformation
March 24, 2018 - Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection
March 24, 2018 - Accelerated WBI Should be the Norm for Most Breast Cancers
March 24, 2018 - Experts seek to standardize treatments for childhood rheumatic diseases
March 24, 2018 - Foil-based measuring chip rapidly detects Legionella
March 24, 2018 - Bariatric surgery linked to positive outcomes in very obese adolescents with type 2 diabetes
March 24, 2018 - Researchers identify chemical responsible for carcinogen formation in recycled wastewater
March 24, 2018 - Obesity and severe obesity continue to rise among U.S. adults
March 24, 2018 - Missed hospital appointments increase after spring clock change in the UK
March 24, 2018 - Researchers explore ways to manage and prevent falls in older adults with dementia
March 24, 2018 - Are there risks from secondhand marijuana smoke? Early science says yes.
March 24, 2018 - NUST MISIS researchers produce elastic metal rods for scoliosis treatment
March 24, 2018 - New University of Bath project seeks to make injections safer
March 24, 2018 - Higher-dose RT does not improve survival but reduces recurrence risk for prostate cancer patients
March 24, 2018 - Researchers examine link between knee pain and depression in older adults
March 24, 2018 - FDA Alert: BD Vacutainer Blood Collection Tubes by Becton, Dickinson and Company (BD): Class I Recall
March 24, 2018 - Daytime Sleepiness Linked to Amyloid Accumulation Without Dementia
March 24, 2018 - Energy storehouses in the brain may be source of Alzheimer’s, targets of new therapy
March 24, 2018 - Praising people with autism shows promise for producing more exercise
March 24, 2018 - Using harmless red or infrared light to diagnose breast cancer
March 24, 2018 - Clash over abortion hobbles a health bill. Again. Here’s how.
March 23, 2018 - Virtual nature environment could be new way to recover from stress
March 23, 2018 - New study identifies key cellular mechanisms behind vascular aging in mice
March 23, 2018 - Nightmares Common Among U.S. Troops, But Seldom Reported
March 23, 2018 - Another Record Low for Tuberculosis in U.S.
March 23, 2018 - Changes in the eye connected to a decline in memory
March 23, 2018 - Radiologist creates dramatic teaching tool using power of VR
March 23, 2018 - Grilled meat could be raising the risk of hypertension finds study
March 23, 2018 - Mutations found in bassoon gene may help explain cause of rare brain disorder
March 23, 2018 - Childhood Brain Injuries May be Linked to ADHD Years Later
March 23, 2018 - Why treating addiction with medication should be carefully considered
March 23, 2018 - Researchers make key discovery about cellular pathway linked to myriad of diseases
March 23, 2018 - Researchers uncover cause of rare childhood neurodegenerative disease
March 23, 2018 - Measles infection in early childhood could contribute to later COPD
March 23, 2018 - Opioid painkiller is top prescription in 11 states
March 23, 2018 - Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-of-Concept Trial of Topical By Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
March 23, 2018 - In Teen Girls, Neural Patterns May Drive Emotional Resilience
March 23, 2018 - Gene-based test for urine detects, monitors bladder cancer
March 23, 2018 - BD to introduce new digital solution for IV chemotherapy administration process at EAHP 2018
March 23, 2018 - New computational method helps to identify tumor cell mutations with greater accuracy
March 23, 2018 - Researchers identify potential obesity treatment in freezing hunger-signaling nerve
March 23, 2018 - Wales participates in the 100,000 Genomes Project
Including Drug to Same old Care Would possibly Extend Lymphoma Survival

Including Drug to Same old Care Would possibly Extend Lymphoma Survival

image_pdfDownload PDFimage_print

HealthDay news image

WEDNESDAY, Sept. 27, 2017 (HealthDay Information) — Lengthy-term remedy with the drug rituximab (Rituxan) might lengthen the lives of a few sufferers with an extraordinary type of blood most cancers, a brand new medical trial unearths.

The illness, referred to as mantle-cell lymphoma, is usually incurable. However quite a lot of therapies can extend other people’s lives. Some sufferers, as an example, are in a position to go through chemotherapy to wipe out the most cancers cells, adopted by way of a stem cellular transplant — to revive customary blood cells.

However whilst that means will also be efficient for some time, maximum sufferers see the most cancers come again.

So the brand new trial, funded by way of Rituxan maker Roche, checked out whether or not an extra step may assist: Having sufferers take Rituxan for 3 years following their stem cellular transplant.

Total, researchers discovered, the strategy did enhance sufferers’ outlook. After 4 years, 83 p.c of rituximab sufferers had been nonetheless alive and progression-free — as opposed to 64 p.c of sufferers who had same old remedy on my own.

Professionals mentioned the findings must have a direct have an effect on on sufferers’ remedy.

“This must be regarded as a brand new same old of care,” mentioned Dr. Anas Younes, leader of the lymphoma carrier at Memorial Sloan Kettering Most cancers Middle, in New York Town.

Alternatively, there are considerations with the long-term use of rituximab, consistent with Younes, who wasn’t concerned within the learn about.

The drug suppresses the immune device, so infections are at all times a possibility, he famous.

“However,” Younes added, “the advantages appear to outweigh the dangers.”

Dr. Steven Le Gouill, of Nantes Scientific College, in France, led the learn about.

He agreed that “rituximab repairs” — the usage of it long-term, after a stem cellular transplant — must turn into a brand new same old.

“The achieve in the case of total survival must inspire hematologists to prescribe rituximab repairs for transplanted sufferers,” Le Gouill mentioned.

Mantle-cell lymphoma is one in every of about 70 subtypes of non-Hodgkin lymphoma, consistent with the Leukemia & Lymphoma Society. In the USA, about four,200 individuals are identified with the illness every 12 months — maximum regularly, older males.

Medical doctors have lengthy used rituximab to regard sure cancers, together with mantle-cell lymphoma. The drug is a lab-engineered antibody that latches onto a protein on white blood cells (lymphocytes) known as B cells; the ones are the cells which are affected in mantle-cell lymphoma.

Because it stands, rituximab is used in conjunction with high-dose chemotherapy medicine to wipe out the cancerous B cells. Some sufferers then go through an “autologous” stem cellular transplant. That implies they’ve a few of their very own blood-forming stem cells got rid of prior to their drug routine; in a while, the stem cells are infused again into the frame, to revive new, wholesome blood cells.

Some sufferers — together with those that are older and frail — can not have a transplant.

However different analysis has proven that rituximab repairs, given after same old drug remedy to power out the most cancers, can lengthen the ones sufferers’ lives, Younes mentioned.

The brand new findings display the similar is correct for sufferers who do have a transplant.

The trial concerned 299 sufferers who had been more youthful than 66 once they had been identified with mantle-cell lymphoma. All underwent same old drug remedy, with rituximab and chemotherapy. Maximum — 86 p.c — spoke back neatly sufficient to go through a stem cellular transplant.

Part of the sufferers had been then randomly assigned to a few years of rituximab repairs remedy, receiving IV infusions of the drug each two months. The remaining had been adopted up with same old care.

After 4 years, 89 p.c of rituximab sufferers had been nonetheless alive, in comparison with 80 p.c within the comparability staff, the investigators discovered.

The rituximab sufferers had been additionally much more likely to stay freed from a most cancers relapse, or severe negative effects — together with critical infections and allergies: That was once true of 79 p.c of rituximab sufferers, as opposed to 61 p.c of sufferers on same old care.

In line with Le Gouill, “Rituximab repairs after stem cellular transplant is one new weapon within the arsenal to struggle towards mantle-cell lymphoma.”

He famous that different therapies were lately authorized — oral medicine that focus on abnormalities at the most cancers cells — whilst nonetheless others are in construction.

Like different antibody medicine, rituximab is pricey — operating 1000’s of greenbacks per thirty days after medical institution fees, consistent with a printed record. Repayment “might be a topic in some nations,” Le Gouill famous.

However, he added, the associated fee needs to be weighed towards the truth that the drug lengthens sufferers’ lives and has “low toxicity.”

Younes mentioned that the “vital message” from the findings is that sufferers’ survival time is constant to enhance.

The learn about findings had been printed Sept. 28 within the New England Magazine of Medication.

SOURCES: Steven Le Gouill, M.D., Ph.D., hematology carrier, Nantes Scientific College, Nantes, France; Anas Younes, M.D., leader, lymphoma carrier, Memorial Sloan Kettering Most cancers Middle, New York Town; Sept. 28, 2017, New England Magazine of Medication

Information tales are written and equipped by way of HealthDay and don’t replicate federal coverage, the perspectives of MedlinePlus, the Nationwide Library of Medication, the Nationwide Institutes of Well being, or the U.S. Division of Well being and Human Products and services.

Tagged with:

About author

Related Articles